Welcome to our dedicated page for Endra Life Sciences SEC filings (Ticker: NDRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENDRA Life Sciences Inc. filings document a Nasdaq-listed medical technology issuer focused on thermoacoustic biomarker imaging and the TAEUS® Liver device for liver fat assessment in steatotic liver disease, MASLD and MASH. Periodic and current reports disclose operating results, clinical-program updates, research and development spending, liquidity, risk factors and common-stock registration matters.
The company’s SEC record also covers material-event reports on private placement financing, at-the-market equity offering arrangements, digital asset treasury disclosures involving HYPE token holdings, supplemental digital-asset risk factors, Nasdaq continued-listing compliance, workforce-related exit costs and strategic-review matters. Proxy materials document director elections, equity incentive plan amendments, auditor matters and other stockholder voting items.
ENDRA Life Sciences director Michael Harsh reported an equity award of 60,324 shares on January 21, 2026. The filing shows these are restricted stock units (RSUs) that convert into common stock on a one-for-one basis and will vest in full on January 21, 2026. The transaction was recorded at a price of $0 per share, indicating a compensatory grant rather than an open-market purchase. Following this award, Harsh beneficially owned 65,710 shares of common stock, and his holdings include unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, acquired 20,000 shares of common stock on January 21, 2026. The shares come from restricted stock units that were granted at a price of $0 per share and convert into common stock on a one-for-one basis. After this transaction, he beneficially owns 20,000 common shares directly. The RSUs are scheduled to vest in full on January 21, 2027, meaning the CFO will receive all underlying shares on that date if vesting conditions are met.
ENDRA Life Sciences director Lou Basenese received a stock-based award from the company. On January 21, 2026, he was granted 60,324 shares of common stock in the form of restricted stock units (RSUs) at a grant price of $0 per share. Each RSU converts into one share of common stock.
The RSUs will vest in full on January 21, 2027, meaning they convert to common shares on that date if vesting conditions are met. After this grant, Basenese beneficially owned a total of 65,709 shares of ENDRA Life Sciences common stock, which the disclosure notes includes unvested RSUs, all held directly.
ENDRA Life Sciences Chief Executive Officer and Director Alexander Y. Tokman received 75,000 shares of common stock on January 21, 2026 as an equity award. These shares represent restricted stock units that convert into common stock on a one-for-one basis and will vest in full on January 21, 2027. Following this grant, Tokman beneficially owned 75,005 shares of ENDRA Life Sciences common stock directly.
ENDRA Life Sciences Inc. reported results of its 2025 annual stockholder meeting. Stockholders approved a Certificate of Amendment to increase the authorized shares of common stock from 20,000,000 to 1,000,000,000, with the change becoming effective upon filing with the Delaware Secretary of State on December 10, 2025.
Stockholders also approved a Second Amendment to the company’s 2016 Omnibus Incentive Plan and re-elected four directors to serve until the next annual meeting. They ratified RBSM LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 and approved executive compensation on an advisory basis, while a proposal to add officer exculpation to the certificate of incorporation did not receive sufficient support.
ENDRA Life Sciences Inc. is registering the resale by existing investors of up to 2,677,680 shares of common stock, including PIPE shares and shares underlying several series of warrants. The company itself is not selling stock in this prospectus and will only receive cash if holders exercise warrants.
The filing also outlines a new digital asset treasury strategy under which ENDRA plans to hold a majority of its treasury reserves in one to five decentralized finance cryptocurrencies, beginning with the HYPE token, and may use proceeds of future financings to buy additional cryptocurrency. As of this prospectus, ENDRA holds approximately 78,863.1 HYPE tokens and expects its share price and reported earnings to be influenced by volatile crypto prices and evolving accounting rules.
ENDRA continues to develop its TAEUS ultrasound platform for liver fat measurement and intends to use a portion of recent private placement proceeds to fund a pilot validation study of its TAEUS liver device while most of those proceeds support the new crypto-focused treasury strategy.
ENDRA Life Sciences (NDRA) updated its Nasdaq compliance status. The company reported a private placement closed on October 15, 2025, issuing 744,340 shares (or prefunded warrants in lieu) and warrants for up to 1,488,680 shares with exercise prices of $6.32 (and $6.81 for a director), generating approximately $4.9 million in gross proceeds. On October 29, 2025, it also entered an at-the-market program with Lucid Capital Markets for up to $1,750,000 in aggregate gross proceeds.
The company purchased 78,863.1 HYPE tokens as part of a digital asset treasury strategy. Based on these actions, ENDRA believes it has regained compliance with Nasdaq’s minimum $2.5 million stockholders’ equity requirement. Nasdaq will continue to monitor compliance and may delist the company if a future periodic report does not evidence compliance.
ENDRA Life Sciences (NDRA) filed its Q3 2025 report, showing no revenue and a narrower net loss. Net loss was $1,595,959 for the quarter and $3,858,201 for nine months. Operating expenses declined year over year as R&D and sales and marketing were reduced while development shifted toward clinical and commercialization activities.
Liquidity remains tight. Cash was $794,036 and working capital was $248,402 as of September 30, 2025, and management disclosed substantial doubt about the ability to continue as a going concern absent additional financing. The company reported a warrant liability remeasurement impact and continued to streamline costs.
Subsequent events: ENDRA closed a private placement on October 15, 2025 for gross proceeds of approximately $4.9 million, established a Digital Asset Treasury and purchased 78,863.1 HYPE tokens valued at about $3,000,000 as of October 21, 2025, and entered a new ATM program on October 29, 2025 for up to $1.75 million. The private placement limits spending on the TAEUS pilot validation study to $750,000. Shares outstanding were 1,166,441 as of November 14, 2025.
ENDRA Life Sciences (NDRA) filed a resale prospectus registering up to 2,677,680 shares of common stock for potential sale by selling stockholders. The registered shares comprise 379,539 PIPE Shares, 364,801 shares underlying pre-funded warrants, 1,488,680 shares underlying common warrants, 400,000 shares underlying Arca warrants, and 44,660 shares underlying placement agent warrants.
The company is not offering shares and will not receive proceeds from stockholder resales; it may receive cash only from any warrant exercises. The common warrants have a per share exercise price of $6.32, and the combined purchase price in the related private placement was $6.57 per share and accompanying warrants. NDRA last traded at $5.205 on November 5, 2025. Shares outstanding were 1,166,441 as of October 16, 2025; this is a baseline figure, not the amount being offered.
ENDRA Life Sciences (NDRA) entered an at-the-market (ATM) sales agreement with Lucid Capital Markets, LLC, allowing the company to offer and sell, from time to time, shares of common stock for aggregate gross proceeds of up to $1,750,000. Sales may be made as “at-the-market” offerings under Rule 415, including directly on or through the Nasdaq Capital Market, and may also include negotiated principal transactions with Lucid. The shares are registered under the company’s shelf registration statement on Form S-3 (File No. 333-277058) and a prospectus supplement dated October 29, 2025.
ENDRA will pay Lucid a commission of up to 3.0% of gross proceeds on shares sold and reimburse specified expenses. The agreement ends upon the earlier of selling all registered shares, termination by either party per its terms, or the three-year anniversary of the agreement. ENDRA is not obligated to sell and may suspend or terminate offers at any time.